Biomarkers for Alzheimer's disease.

  title={Biomarkers for Alzheimer's disease.},
  author={Ernest K. J. Pauwels and Duccio Volterrani and Giuliano Mariani},
  journal={Drug news & perspectives},
  volume={22 3},
It has been determined that patients suffering from mild cognitive impairment (MCI) may progress to Alzheimer's disease (AD), which offers a window for therapeutic intervention to slow or halt disease progression. Thus, the detection of prodromal AD is essential to initiate early treatment. The key pathologic hallmark of AD is amyloid beta peptide 42 (Abeta(42)). Probably because of its direct contact with brain tissue, levels of Abeta(42) in combination with phosphorylated tau determined in… CONTINUE READING